Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Craig Hallum from a "hold" rating to a "strong-buy" rating.
Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target raised by analysts at Wells Fargo & Company from $3.00 to $5.00. They now have an "equal weight" rating on the stock.
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "market outperform" rating. They now have a $8.00 price target on the stock.
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.